CMS' (Centers for Medicare & Medicaid Services) OPT (ocular photodynamic therapy) with verteporfin decision cheers QLT/Novartis
This article was originally published in Clinica
Executive Summary
The Centers for Medicare & Medicaid Services (CMS) has finally settled on a coverage policy for ocular photodynamic therapy (OPT) with verteporfin, the only known treatment of the eye condition known as age-related macular degeneration (AMD). The agency announced on January 29 that it is prepared to cover the product for patients with two forms of "wet" AMD caused by the development of abnormally leaky blood vessels known as choroidal neovascularisation (CNV).
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.